Clinical Study
Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma
Table 3
HCC recurrence and survival outcomes.
| | Response | Sorafenib adjuvant therapy
| Historical comparison group
| value |
| | Recurrent HCC (%) | 2 (29) | 9 (75) | 0.07 | | Median recurrent time from OLT (days) | 1053 | 620 | 0.08 | | 1-year disease-free survival | 7 (100) | 8 (66) | | | 1-year overall survival (%) | 7 (100) | 11 (91.6) | 0.63 | | Mean follow-up duration in days (SD) | 1125 (310) | 840 (483) | 0.18 |
|
|
